Pharmacologic activity and pharmacokinetics of metabolites of regorafenib in preclinical models.
about
Regorafenib as treatment for patients with advanced hepatocellular cancer.A Multikinase and DNA-PK Inhibitor Combination Immunomodulates Melanomas, Suppresses Tumor Progression, and Enhances Immunotherapies.Antitumor effects of regorafenib and sorafenib in preclinical models of hepatocellular carcinoma.Mass balance, metabolic disposition, and pharmacokinetics of a single oral dose of regorafenib in healthy human subjects.Evolution of regorafenib from bench to bedside in colorectal cancer: Is it an attractive option or merely a "me too" drug?Current Molecular Targeted Therapies for Bone and Soft Tissue Sarcomas.
P2860
Pharmacologic activity and pharmacokinetics of metabolites of regorafenib in preclinical models.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 13 October 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Pharmacologic activity and pha ...... rafenib in preclinical models.
@en
Pharmacologic activity and pha ...... rafenib in preclinical models.
@nl
type
label
Pharmacologic activity and pha ...... rafenib in preclinical models.
@en
Pharmacologic activity and pha ...... rafenib in preclinical models.
@nl
prefLabel
Pharmacologic activity and pha ...... rafenib in preclinical models.
@en
Pharmacologic activity and pha ...... rafenib in preclinical models.
@nl
P2093
P2860
P356
P1433
P1476
Pharmacologic activity and pha ...... rafenib in preclinical models.
@en
P2093
Ajay Bhargava
Dieter Zopf
Frank-Thorsten Hafner
Iduna Fichtner
Karl-Heinz Thierauch
Konstanze Diefenbach
Michael Gerisch
Scott Wilhelm
Wolfram Steinke
P2860
P304
P356
10.1002/CAM4.883
P407
P577
2016-10-13T00:00:00Z